Abstract 13330: Depression is Associated With Cardiovascular Events in Male but Not Female Patients With One or More Cardiovascular Risk Factors: Japan Morning Surge Home Blood Pressure (J-HOP) Study
Introduction: Depression is associated with cardiovascular events, and the frequency of depression is higher in females than in males. However, the association between depression and cardiovascular events in patients with cardiovascular risk factors and the gender difference of the association remains unclear.
Hypothesis: We assessed the hypothesis that depression was associated with a poor prognosis in patients with cardiovascular risk factors, and that the association is different in males and females.
Methods: We enrolled 3,216 patients in the Japan Morning Surge Home Blood Pressure Study who had one or more cardiovascular risk factors. We conducted the Beck Depression Inventory (BDI). Depression was defined as having a BDI score ≥ 16. The primary endpoints were fatal/nonfatal cardiovascular events (myocardial infarction, stroke, hospitalization for heart failure, aortic dissection).
Results: The mean follow-up period was 47±24 months, and 134 patients suffered primary endpoints. In male patients, depressive patients (N=184) were more likely to suffer cardiovascular events than non-depressive patients (N=1439) (log rank 6.79, p=0.009). In female patients, cardiovascular events were similar in depressive (N=347) and nondepressive patients (N=1246,log rank 0.06, p=0.81). A Cox proportional hazards model including age, history of hypertension, dyslipidemia and diabetes revealed that depression was a significant, independent predictor of primary endpoints in male patients (hazard ratio 2.01, 95% confidence interval 1.20-3.37, p=0.008).
Conclusions: Depression is associated with cardiovascular events in male but not female patients with one or more cardiovascular risk factors.
Author Disclosures: T. Kabutoya: Honoraria; Modest; Medtronic Japan Co., Ltd., Daiichi Sankyo, Co. Ltd., Bayer Yakuhin Ltd., Meiji Seika Pharma Co., Ltd.. S. Hoshide: None. K. Kario: Research Grant; Significant; Teijin Pharma Limited, Novartis Pharma K.K., Takeda Pharmaceutical Co., Ltd., OMRON HEALTHCARE Co., Ltd., FUKUDA DENSHI. Honoraria; Modest; Mitsubishi Tanabe Pharma Corporation., Kyowa Hakko Kirin Co., Ltd., Bayer Yakuhin Ltd., Pfizer Japan Inc., Shionogi & Co., Ltd., Astellas Pharma Inc., AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Sanofi K.K., GlaxoSmithKline K.K., TERUMO Corporation., Bristol-Myers K.K., Kowa Pharmaceutical Co. Ltd., Medtronic Japan Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Roche Diagnostics K.K., MSD K.K.. Honoraria; Significant; Mochida Pharmaceutical Co.,Ltd., Takeda Pharmaceutical Co.,Ltd., Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd..
- © 2015 by American Heart Association, Inc.